We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Novel ALS Therapy in Human Clinical Trials

News   Jul 17, 2018 | Original Story by Tamara Bhandari for WUSTL

 
Novel ALS Therapy in Human Clinical Trials

Robert Bucelli, MD, PhD, measures Gregory Easter's neuromuscular function. Easter, who has an inherited form of amytrophic lateral sclerosis, a fatal neuromuscular disease, is taking part in a clinical trial to evaluate an experimental drug. New research at Washington University School of Medicine in St. Louis shows the drug extends survival and reverses some neuromuscular damage in mice and rats and may help people whose disease is caused by mutations in the gene SOD1. Credit: Mike Worful, WUSTL.

 
 
 

RELATED ARTICLES

Reducing Heart Attack-induced Tissue Damage by 30%

News

Scientists have discovered that inhibiting the synthesis of a lipid in a mouse suffering a heart attack reduces the tissue damage by 30%.

READ MORE

Motor Matter: How Myelin Is Essential for Movement

News

A team of researchers has established the neural circuit basis for motor learning tasks when myelination is impaired.

READ MORE

Against the Clock, People Tell You What You Want To Hear

News

When asked to answer questions quickly and impulsively, people tend to respond with a socially desirable answer rather than an honest one, a set of experiments shows.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE